Dispatch Bio has officially launched with a stated mission to engineer a universal treatment across solid tumours.  Immunotherapies have struggled to effectively treat solid tumours due to the lack of a tumour-specific target and the presence of an immune-suppressive tumour microenvironment.   Dispatch’s Flare platform has been engineered to overcome these. It works by delivering a […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!